ASHLEY HALL

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health LEBANON, TN NPI 1366733396

General Payments — all program years on this page

$1,884.00

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 85
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $460.63 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $375.6417
Education $84.991

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Astellas Pharma US Inc $121.193
AIMMUNE THERAPEUTICS, INC. $90.911
Novo Nordisk AS $59.773
ABBVIE INC. $48.173
Acerta Pharma LLC $46.993
Ferring Pharmaceuticals Inc. $26.341
Amgen Inc. $20.211
PFIZER INC. $18.801
Lilly USA, LLC $14.441
Abbott Laboratories $13.811

By program year

Program yearAmountRecords
2021 $353.3218
2022 $698.6524
2023 $371.4025
2024 $460.6318

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100247230 Novo Nordisk Inc $21.77 10/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100565192 Novo Nordisk Inc $24.06 05/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100568800 Novo Nordisk Inc $13.94 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104260127 AstraZeneca Pharmaceuticals LP $15.63 06/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104648227 AstraZeneca Pharmaceuticals LP $15.90 07/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105751089 AstraZeneca Pharmaceuticals LP $15.46 09/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107274960 ABBVIE INC. $13.82 01/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107274962 ABBVIE INC. $16.15 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107274964 ABBVIE INC. $18.20 06/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115695261 Amgen Inc. $20.21 08/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125029493 Abbott Laboratories $13.81 08/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1132078265 PFIZER INC. $18.80 10/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135569963 Lilly USA, LLC $14.44 11/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137530659 Ferring Pharmaceuticals Inc. $26.34 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139491544 Astellas Pharma US Inc $13.89 02/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139495994 Astellas Pharma US Inc $22.31 03/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139507595 Astellas Pharma US Inc $84.99 05/09/2024 Education Undisputed 01/23/2026 View at CMS
1146972497 AIMMUNE THERAPEUTICS, INC. $90.91 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.